会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明授权
    • Apparatus, method, and computer program product for high-availability multi-agent cryptographic key recovery
    • 用于高可用性多代理加密密钥恢复的装置,方法和计算机程序产品
    • US06396929B1
    • 2002-05-28
    • US09224892
    • 1998-12-31
    • Sekar ChandersekaranSohail MalikMichael MuresanNarayanan Vasudevan
    • Sekar ChandersekaranSohail MalikMichael MuresanNarayanan Vasudevan
    • H04L930
    • H04L9/0894
    • An apparatus, method, and computer program product for high-availability multi-agent cryptographic key recovery. The present invention defines a key recovery block that specifies allowable subsets of the total set of key recovery agents that can participate in a key recovery. For each subset, key recovery information is computed and stored after the subset is specified. This key recovery information is only useable by that subset because it is computed using that subset of public keys of the agents. When key recovery is initiated, a trusted processor (a key recovery coordinator) validates the contents of the key recovery block and it uses and is allowed to use any of the subsets of the agents to process the key recovery request. Since many subsets could be specified, the likelihood of key recovery failure is greatly diminished.
    • 一种用于高可用性多代理加密密钥恢复的设备,方法和计算机程序产品。 本发明定义了密钥恢复块,其指定可以参与密钥恢复的密钥恢复代理的总组的可允许子集。 对于每个子集,在子集被指定之后,计算并存储密钥恢复信息。 该密钥恢复信息只能由该子集使用,因为它是使用代理的公钥的该子集来计算的。 当启动密钥恢复时,受信任的处理器(密钥恢复协调器)验证密钥恢复块的内容,并使用密钥恢复块,并允许其使用代理的任何子集来处理密钥恢复请求。 由于可以指定许多子集,因此密钥恢复失败的可能性大大降低。
    • 7. 发明授权
    • Identification of compounds for inhibiting complexation of C-reactive protein with fibronectin
    • 鉴定用于抑制C-反应蛋白与纤连蛋白复合的化合物
    • US07645583B2
    • 2010-01-12
    • US11302994
    • 2005-12-14
    • RameshBabu BogaSohail MalikStephen Quirk
    • RameshBabu BogaSohail MalikStephen Quirk
    • G01N33/53G01N33/533G01N21/76
    • G01N33/558G01N33/68G01N2333/4737G01N2333/78G01N2500/02Y10S436/815
    • Disclosed are screening processes for identification of compounds that may inhibit complex formation between C-reactive protein and fibronectin. Compounds identified by the disclosed methods may be utilized to inhibit the target analytes that are known to occur during skin aging as well as during the course of several diseases. Accordingly, inhibitory compounds identified by the disclosed methods may be utilized to prevent and treat damaged tissue, inflammatory conditions, cardiovascular conditions, renal conditions, periodontal conditions and obesity, among other conditions. For example, the compounds identified by the disclosed methods may be utilized to treat tissue that has suffered trauma, e.g., burns or wounds, as well as tissue that is inflamed due to any of several causes. The disclosed compounds may also be utilized to improve the accuracy of assays designed to assess CRP or Fn levels in a sample, for instance in a plasma sample, as a risk assessment tool in certain medical conditions and to discover new treatments.
    • 公开了用于鉴定可能抑制C-反应蛋白和纤连蛋白之间的复合物形成的化合物的筛选方法。 通过公开的方法鉴定的化合物可以用于抑制已知在皮肤老化期间以及在几种疾病过程中发生的目标分析物。 因此,通过所公开的方法鉴定的抑制性化合物可以用于预防和治疗受损组织,炎性病症,心血管病,肾病,牙周病和肥胖等疾病。 例如,通过所公开的方法鉴定的化合物可以用于治疗已经遭受创伤的组织,例如烧伤或伤口,以及由于几种原因中的任何一种而发炎的组织。 所公开的化合物还可以用于提高设计用于评估样品中的CRP或Fn水平的测定的准确度,例如在血浆样品中,作为某些医疗条件下的风险评估工具并发现新的治疗。